---
id: 042
title: Rifampin Mechanism and Drug Interactions
category: antimicrobials
subcategory: rifamycins
tags: [rifampin, tuberculosis, CYP3A4, drug-interactions, RIPE]
difficulty: hard
---

## Question

What is rifampin's mechanism of action, and why does it cause extensive **drug interactions**?

## Answer

### **Mechanism of Action:**
- Inhibits bacterial **DNA-dependent RNA polymerase (RNAP)**
- Blocks RNA synthesis by preventing elongation
- **Bactericidal** against both replicating and non-replicating bacteria
- Unique to bacteria (does not affect human RNAP)

### **Why Extensive Drug Interactions:**

**Rifampin is a POTENT inducer of:**
- **CYP3A4** (80-fold induction - most significant)
- CYP2C9, CYP2C19, CYP2C8, CYP1A2
- **P-glycoprotein** (efflux transporter)
- UGT1A1 (glucuronosyltransferase)

**Mechanism:** Activates **nuclear pregnane X receptor (PXR)** → transcriptional upregulation of enzymes

### **Clinical Impact - Rifampin DECREASES levels of:**

| Drug Class | Examples | Clinical Effect |
|------------|----------|-----------------|
| **Antiretrovirals** | Protease inhibitors, NNRTIs | Subtherapeutic HIV drugs → resistance |
| **Anticoagulants** | Warfarin | ↓ INR → thrombosis risk |
| **Immunosuppressants** | Tacrolimus, cyclosporine | Rejection risk |
| **Antifungals** | Voriconazole, itraconazole | Treatment failure |
| **Oral contraceptives** | Estrogen/progesterone | Contraceptive failure |
| **Anticonvulsants** | Phenytoin (variable) | Seizure risk |

### **Rifamycin Comparison (CYP Induction Potency):**
**Rifampin > Rifapentine > Rifabutin >> Rifaximin (minimal)**

## Key Points

### **RIPE Therapy for Active TB:**
- **R**ifampin
- **I**soniazid
- **P**yrazinamide
- **E**thambutol

**Duration:** 2 months RIPE → 4 months RI (total 6 months)

### **Latent TB:**
- Rifampin monotherapy: 4 months daily
- Alternative to isoniazid (fewer hepatotoxicity concerns)

### **Clinical Pearls:**
- Turns body fluids **orange-red** (urine, tears, sweat) - warn patients
- Can permanently stain soft contact lenses
- Monitor drug interactions closely - may need dose adjustments or alternative agents
- Resistance develops rapidly if used as monotherapy (except LTBI)

## Sources

- [PMC1395332: Rifampicin Drug-Drug Interactions via PXR]
- [StatPearls NBK557488: Rifampin]
- [Nature 2020: Hepatocytic Signatures of Rifamycin Drug Interactions]

## Media

N/A
